Publication

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

Batchelor, T
; 
Mulholland, P
; 
Neyns, B
; 
Nabors, L
; 
Campone, M
; 
Wick, A
; 
Mason, W
; 
Mikkelsen, T
; 
Phuphanich, S
; 
Ashby, L
... show 10 more
Citations
Altmetric:
Abstract
A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma.
Authors
Batchelor, T
Mulholland, P
Neyns, B
Nabors, L
Campone, M
Wick, A
Mason, W
Mikkelsen, T
Phuphanich, S
Ashby, L
Degroot, J
Gattamaneni, Rao
Cher, L
Rosenthal, M
Payer, F
Jürgensmeier, J
Jain, R
Sorensen, A
Xu, J
Liu, Q
van den Bent, M
Affiliation
Tracy T. Batchelor, Rakesh K. Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA; Paul Mulholland, University College London, London; Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Mario Campone, Centre Rene Gauducheau, Saint-Herblain, France; Antje Wick, University of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Tom Mikkelsen, Henry Ford Hospital, Detroit, MI; Surasak Phuphanich, Cedars-Sinai Medical Center, Los Angeles, CA; Lynn S. Ashby, Barrow Neurological Institute, Phoenix, AZ; John DeGroot, MD Anderson Cancer Center, Houston, TX; Lawrence Cher, Austin Health Cancer Services; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Australia; Franz Payer, Medical University, Graz, Austria; Juliane M. Jürgensmeier, John Xu, and Qi Liu, AstraZeneca, Wilmington, DE; and Martin van den Bent, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
Description
Date
2013-08-12
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. 2013: J Clin Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/300435
Embedded videos